[1] Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J clin, 2011, 61: 69-90.
[2] Schutte K, Bornschein J, Malfertheiner P, et al. Hepatocellular carcinoma- epidemiological trends and risk factors. Dig Dis, 2009, 27: 80-92.
[3] Lohitesh K, Chowdhury R, Mukherjee S. Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight. Cancer Cell Int, 2018, 18: 44-58.
[4] Kaseb AO, Shindoh J, Patt YZ, et al. Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. Cancer, 2013, 119: 3334-3342.
[5] Deng GL, Zeng S, Shen H. Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges. World J Hepatol, 2015, 7: 787-798.
[6] Erdmann VA, Szymanski M, Hochberg A, et al. Collection of mRNA-like non-coding RNAs. Nucleic Acids Res, 1999, 27: 192-195.
[7] Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell, 2009, 136: 629-641.
[8] Wong CM, Tsang FH, Ng IO. Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications. Nat Rev Gastroenterol Hepatol, 2018, 15: 137-151.
[9] Batista PJ, Chang HY. Long noncoding RNAs: cellular address codes in development and disease. Cell, 2013, 152: 1298-1307.
[10] Ayers D, Vandesompele J. Influence of microRNAs and long non-coding RNAs in cancer chemoresistance. Genes, 2017, 8: 95.
[11] Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol, 2005, 204: 216-237.
[12] Tsang WP, Kwok TT. Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells. Oncogene, 2007, 26: 4877-4881.
[13] Yang LT, Du Y, Yu PF, et al. Long non-coding RNA TUG1 regulates the development of multidrug resistance in hepatocellular carcinoma via P-gp and MDR1. Int J Clin Exp Med, 2016, 9: 21388-21396.
[14] Takahashi K, Yan IK, Wood J, et al. Involvement of extracellular vesicle long noncoding RNA (linc-VLDLR) in tumor cell responses to chemotherapy. Mol Cancer Res, 2014, 12: 1377-1387.
[15] Wu WK, Coffelt SB, Cho CH, et al. The autophagic paradox in cancer therapy. Oncogene, 2011, 31: 939-953.
[16] Song J, Qu Z, Guo X, et al. Hypoxia-induced autophagy contributes to the chemoresistance of hepatocellular carcinoma cells. Autophagy, 2009, 5: 1131-1144.
[17] Yuan P, Cao W, Zang Q, et al. The HIF-2α-MALAT1-miR-216b axis regulates multi-drug resistance of hepatocellular carcinoma cells via modulating autophagy. Biochem Biophys Res Commun, 2016, 478: 1067-1073.
[18] Xiong H, Ni Z, He J, et al. LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells. Oncogene, 2017, 36: 3528-3540.
[19] Lv L, Chen G, Zhou J, et al. WT1-AS promotes cell apoptosis in hepatocellular carcinoma through down-regulating of WT1. J Exp Clin Cancer Res, 2015, 34: 119.
[20] Xiao J, Lv Y, Jin F, et al. LncRNA HANR promotes tumorigenesis and increase of chemoresistance in hepatocellular carcinoma. Cell Physiol Biochem, 2017, 43: 1926-1938.
[21] Jin W, Chen L, Cai X, et al. Long non-coding RNA TUC338 is functionally involved in sorafenib-sensitized hepatocarcinoma cells by targeting RASAL1. Onco Rep, 2017, 37: 273-280.
[22] Beck B, Blanpain C. Unravelling cancer stem cell potential. Nat Rev Cancer, 2013, 13: 727-738.
[23] Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell, 2014, 14: 275-291.
[24] Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell, 2012, 149: 1192-1205.
[25] Wang Y, He L, Du Y, et al. The Long noncoding RNA lncTCF7 promotes self-renewal of human liver cancer stem cells through activation of Wnt signaling. Cell Stem Cell, 2015, 16: 413-425.
[26] Chen Z, Gao Y, Yao L, et al. LncFZD6 initiates Wnt/β-catenin and liver TIC self-renewal through BRG1-mediated FZD6 transcriptional activation. Oncogene, 2018, doi: 10.1038/s41388-018-0203-6.
[27] Fu X, Zhu X, Qin F, et al. Linc00210 drives Wnt/β-catenin signaling activation and liver tumor progression through CTNNBIP1-dependent manner. Mol Cancer, 2018, 17: 73.
[28] Zhu P, Wang Y, Wu J, et al. LncBRM initiates YAP1 signalling activation to drive self-renewal of liver cancer stem cells. Nat Commun, 2016, 7: 13608.
[29] Li Y, Ye Y, Feng B, et al. Long noncoding RNA lncARSR promotes doxorubicin resistance in hepatocellular carcinoma via modulating PTEN-PI3K/Akt pathway. J Cell Biochem, 2017, 118: 4498-4507.
[30] Qu L, Wu Z, Li Y, et al. A feed-forward loop between lncARSR and YAP activity promotes expansion of renal tumour-initiating cells. Nat Commun, 2016, 7: 12692.
[31] Chen Z, Liu Y, Yao L, et al. The long noncoding RNA lncZic2 drives the self-renewal of liver tumor-initiating cells via the protein kinase C substrates MARCKS and MARCKSL1. J Bio Chem, 2018, jbc.RA117.001321.
[32] Takahashi K, Yan IK, Kogure T, et al. Extracellular vesicle-mediated transfer of long non-coding RNA ROR modulates chemosensitivity in human hepatocellular cancer. FEBS Open Bio, 2014, 4: 458-467.
[33] Wang X, Sun W, Shen W, et al. Long non-coding RNA DILC regulates liver cancer stem cells via IL-6/STAT3 axis. J Hepatol, 2016, 64: 1283-1294. |
